lapatinib stada 250 mg comprimidos recubiertos con pelicula efg
laboratorio stada s.l. - lapatinib - comprimido recubierto con pelÍcula - 250 mg - lapatinib 250 mg - lapatinib
dasatinib teva 100 mg comprimidos recubiertos con pelicula efg
teva b.v. - dasatinib monohidrato - comprimido recubierto con pelÍcula - 100 mg - dasatinib monohidrato 100 mg - dasatinib
dasatinib teva 50 mg comprimidos recubiertos con pelicula efg
teva b.v. - dasatinib monohidrato - comprimido recubierto con pelÍcula - 50 mg - dasatinib monohidrato 50 mg - dasatinib
dasatinib teva 70 mg comprimidos recubiertos con pelicula efg
teva b.v. - dasatinib monohidrato - comprimido recubierto con pelÍcula - 70 mg - dasatinib monohidrato 70 mg - dasatinib
dasatinib stada 50 mg comprimidos recubiertos con pelicula efg
laboratorio stada s.l. - dasatinib - comprimido recubierto con pelÍcula - 50 mg - dasatinib 50 mg - dasatinib
dasatinib stada 70 mg comprimidos recubiertos con pelicula efg
laboratorio stada s.l. - dasatinib - comprimido recubierto con pelÍcula - 70 mg - dasatinib 70 mg - dasatinib
dasatinib viatris 50 mg comprimidos recubiertos con pelicula efg
viatris limited - dasatinib - comprimido recubierto con pelÍcula - 50 mg - dasatinib 50 mg - dasatinib
dasatinib viatris 70 mg comprimidos recubiertos con pelicula efg
viatris limited - dasatinib - comprimido recubierto con pelÍcula - 70 mg - dasatinib 70 mg - dasatinib
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agentes antineoplásicos - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agentes antineoplásicos - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.